-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, QFWBKWWEKNg13s8BruQypDPNQkV3kDFJ4a41SeEotuXlkin3xYLOSMUHzhdQjrs/ 5+uULIexnYdlaqsgjilk8w== 0000947871-07-000665.txt : 20070514 0000947871-07-000665.hdr.sgml : 20070514 20070514111157 ACCESSION NUMBER: 0000947871-07-000665 CONFORMED SUBMISSION TYPE: 424B3 PUBLIC DOCUMENT COUNT: 2 FILED AS OF DATE: 20070514 DATE AS OF CHANGE: 20070514 FILER: COMPANY DATA: COMPANY CONFORMED NAME: MERRILL LYNCH PIERCE FENNER & SMITH INC CENTRAL INDEX KEY: 0000728612 STANDARD INDUSTRIAL CLASSIFICATION: SECURITY BROKERS, DEALERS & FLOTATION COMPANIES [6211] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 424B3 SEC ACT: 1933 Act SEC FILE NUMBER: 333-89355 FILM NUMBER: 07844637 BUSINESS ADDRESS: STREET 1: 4 WORLD FINANCIAL CENTER STREET 2: NORTH TOWER CITY: NEW YORK STATE: NY ZIP: 10080 BUSINESS PHONE: 2126702273 MAIL ADDRESS: STREET 1: 4 WORLD FINANCIAL CENTER STREET 2: NORTH TOWER CITY: NEW YORK STATE: NY ZIP: 10080 424B3 1 f424b3_051007-biotech.htm BIOTECH

 

PROSPECTUS SUPPLEMENT

 

REGISTRATION NO. 333-89355

(To Prospectus dated February 17, 2006)

 

Filed Pursuant to Rule 424(b)(3)

 

 

 

 

1,000,000,000 Depositary Receipts
Biotech HOLDRS (SM) Trust

 

 

This prospectus supplement supplements information contained in the prospectus dated February 17, 2006 relating to the sale of up to 1,000,000,000 depositary receipts by the Biotech HOLDRS (SM) Trust.

 

The share amounts specified in the table in the “Highlights of Biotech HOLDRS” section of the base prospectus shall be replaced with the following:

 

Name of Company(1)

 

Ticker

 

Share
Amounts

 

Primary
Trading Market

Affymetrix, Inc.

 

AFFX

 

4

 

NASDAQ

Alkermes, Inc.

 

ALKS

 

4

 

NASDAQ

Amgen Inc.

 

AMGN

 

64.48

 

NASDAQ

Applera Corporation—Applied Biosystems Group*

 

ABI

 

18

 

NYSE

Applera Corporation—Celera Genomics Group*

 

CRA

 

4

 

NYSE

Biogen IDEC Inc.

 

BIIB

 

26.95

 

NASDAQ

Enzon Pharmaceuticals, Inc.

 

ENZN

 

3

 

NASDAQ

Genentech, Inc.

 

DNA

 

88

 

NYSE

Genzyme Corporation

 

GENZ

 

14

 

NASDAQ

Gilead Sciences, Inc.

 

GILD

 

32

 

NASDAQ

Human Genome Sciences, Inc.

 

HGSI

 

8

 

NASDAQ

MedImmune, Inc.

 

MEDI

 

15

 

NASDAQ

Millennium Pharmaceuticals, Inc.

 

MLNM

 

12

 

NASDAQ

QLT Inc.

 

QLTI

 

5

 

NASDAQ

Sepracor Inc.

 

SEPR

 

6

 

NASDAQ

Shire p.l.c.

 

SHPGY

 

6.8271

 

NASDAQ

 

* The securities of this company trade as a tracking stock. Please see “Risk Factors” and the business description in Annex A for additional information relating to an investment in tracking stock.

 

(1)          Effective January 30, 2007, as a result of the merger of ICOS Corporation (NASDAQ ticker: “ICOS”), an underlying constituent of the Biotech HOLDRS Trust, and Eli Lilly & Co., ICOS Corporation is no longer an underlying constituent of the Biotech HOLDRS Trust. For each share of ICOS Corporation held, shareholders received $34.00 in cash. For the 4 shares of ICOS Corporation per 100 shares round lot of Biotech HOLDRS, The Bank of New York received $136.00 in cash. The Bank of New York distributed the cash at a rate of $1.3567 per depositary share of Biotech HOLDRS on February 9, 2007. The record date for such distribution was February 7, 2007.

 

The share amounts listed in the table above reflect all previous stock splits, dividends and business combination transactions.

 

The date of this prospectus supplement is March 31, 2007.

 

 

 

 GRAPHIC 2 img1.gif GRAPHIC begin 644 img1.gif M1TE&.#EA2P%7`'<``"'_"TU33T9&24-%.2XP#0````%S4D="`*[.'.D`(?\+ M35-/1D9)0T4Y+C`8````#&US3U!-4T]&1DE#13DN,!.;*91D`"P`````2P%7 M`(0O?[\P?[\P?\`P@,"_O[^PL+"OKZ^@H*#?W]_0T-#/S\_`P,#OD`#@CP#@ MD`#P\/#O[^_@X.#___\!`@,!`@,!`@,!`@,!`@,!`@,!`@,!`@,!`@,!`@,! M`@,!`@,!`@,%_Z`DCF1IGFBJKFSKOG`LSW1MWWBN[WSO_\"@<$@L&H_(I'+) M;#J?T*AT2JU:K]BL=LOM>K_@L'A,+IO/Z+1ZS6Z[W_"X?$ZOV^_XO'[/[_O_ M@'0/$H,DA82!B8J+C(U&@P(``P&1DY64B"*'CIR*`9^@`2.AH9VFBI<"F8B# M#ZZ2E`"MJZ>U=*4HLZVDL[:^<98CNJS$K@^P`@\0KL2_SF:@AL+3*:#&S<_9 M89(GP[TED+#+UYO:YG6AQN7G['.6LNKM\G/IU_//#`T,#ODS^OP-M%QRM6P$ MP'T,A!Q5'H'`G$F3YHV:.'&FS,D3YG3#-RA#HU M)HRJ&[.&="BA:,F@,L#.^"2DI.]_J1`OTI5"*_KC.F#0D MU@!C!44P5`BR154:7ET\#?O0S\RX;6.0+6OVT.,@:5G4A&Q55Q[Y M!>X4\>W/OX/U:?]_I@5`70_(``#!@==I0@C_:S^,9Y]MT.DU6W@/^I?5CS\9 M\MT/W1G66`P7SMA12D8FF8:+<*U`5CP^D!(`CSW"IR(.5^*WGPI,LFA,6"V9Y0DJ6G-=E3E( MJ4R;@0'Z9PV+KKBEEF#J6<2C7V#X`ITC5`+8@<6L^LZ->*UFNZ')ZHK!8 M(CN"EU<]NMFK\'KA:@N8OH/`OX3*$,ZG`?R+@)LNJ,J#LB1LA)BX)3A\+(UG MD/NNI!*`\NS!Z=;P0*Z?;/QLM,&"J5^D\EJ9[[TMHHRQF`R?T)U?`21@\Z@V MT'R)P1$@P*NW>19Y:=!\8D1#MZUFRT*20?N9\KSSD:+``@E$0,MN(->=(=(HT%G@`@LHT#$,TU9B>.(0LV#^ MO<;TA6I8G&+4I!!0-B,S@"X;8]ZJ>A(]__6 M_Y)Z]3VH1PDR`FE>ZS@H"DR]]9NIUW[$,01?TF/NP,T!VR[\AZ\7GRO; MOW-]]_#,P]#;QZ'GSGONLE?M\_+-9U^#\=P'T';;"G`,@?8E_):Q*"+\9GSZ MN*RWGBF#2"\_YP,40`#R;KMIM_8Z2W#:_-&+1<9"-\!,`>`7W0.9_0B0O(-] M@WRC4!_ZW(>^C$6P0Q0\G_D4\3Q"3(]^`3"``0K`MME]3AK8DX>.)!`)$;10 M!-P0P5%DZ!<8SI`$T_)%(3YFO`.(T'[)@Q8U(%B^"8IB,AE,7P2+N,0DGD(7 M/5-``9!A@`-8T8HB%.']$%"U_1&1!/W[7_]<:,"2=PP0&>E3A0L/^`R"1&!J M!"#`"$=H/ZK];AR,^^(%D5C!#5J0?>WKT/F6:`YG]J,E.>O*35:".*%?!25":,@66/-TI5XE"<*@RE:R, KI2QG2 -----END PRIVACY-ENHANCED MESSAGE-----